login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
BLACK DIAMOND THERAPEUTICS I (BDTX) Stock News
USA
- NASDAQ:BDTX -
US09203E1055
-
Common Stock
3.91
USD
-0.01 (-0.26%)
Last: 10/7/2025, 8:11:10 PM
3.81
USD
-0.1 (-2.56%)
Pre-Market:
10/8/2025, 5:29:26 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
BDTX Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: Zacks Investment Research
- Mentions:
AZN
JNJ
BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
a month ago - By: Zacks Investment Research
- Mentions:
AZN
JNJ
Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?
2 months ago - By: Zacks Investment Research
Black Diamond (BDTX) Upgraded to Strong Buy: Here's Why
2 months ago - By: Zacks Investment Research
- Mentions:
BRTX
Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?
2 months ago - By: The Motley Fool
Black Diamond (BDTX) Q2 Loss Narrows 47%
2 months ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2 months ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
3 months ago - By: Yahoo Finance
- Mentions:
RJF
Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows Promise
4 months ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
5 months ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
5 months ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
6 months ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
7 months ago - By: Stocktwits
- Mentions:
VTI
IWM
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High
7 months ago - By: Benzinga
- Mentions:
CANF
TNXP
HQY
INTS
...
12 Health Care Stocks Moving In Wednesday's Intraday Session
7 months ago - By: Benzinga
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million
7 months ago - By: Black Diamond Therapeutics, Inc
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
7 months ago - By: Black Diamond Therapeutics, Inc
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
7 months ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
7 months ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
a year ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
a year ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
a year ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
a year ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
a year ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
a year ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
a year ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
a year ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
a year ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
a year ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
a year ago - By: Black Diamond Therapeutics, Inc
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
Please enable JavaScript to continue using this application.